Evidence map›Paper›PMID 33861995›Full record

ArticleCancer cell2021

Seeing the forest for the trees-single-cell atlases link CD8

Mei Yee Koh, Nicolas Sayegh, Neeraj Agarwal

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Macrophages as tools and targets in cancer therapy.Nature reviews. Drug discovery · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mei Yee KohHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112; Department of Pharmacology and Toxicology, University of Utah, 30S 2000E, Salt Lake City, UT 84112.
Nicolas SayeghHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112.
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112. Electronic address: neeraj.agarwal@hci.utah.edu.
University of Utah · US

Funding

A novel approach for the selective inhibition of HIF-2a in kidney cancerR01CA217905 · NCI · UNIVERSITY OF UTAH · PI KOH, MEI YEE · 2017 to 2021
$1.7M
NCI NIH HHS R01 CA217905
6 · The paper itself

Abstract

Intra- and interpatient heterogeneity of clear cell renal cell carcinoma (ccRCC) confounds the search for therapies associated with durable tumor responses and predictive biomarkers. Here, Braun et. al., Krishna et.al, and Bi et.al. use single-cell mRNA sequencing to characterize progressive immune dysfunction associated with ccRCC progression and resistance to immunotherapies.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCD8-Positive T-LymphocytesDisease ProgressionHumansMacrophagesbiomarkersCD8(+) T cellsimmune checkpoint blockadekidney cancermacrophagesingle-cell RNA sequencing

Identifiers

PMID33861995
OpenAlexW3156752254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.